Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06WARSAW308, POLAND: Comment on Pharma's Special 301 Input

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06WARSAW308.
Reference ID Created Released Classification Origin
06WARSAW308 2006-02-24 15:47 2011-08-24 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Warsaw
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 02 WARSAW 000308 
 
SIPDIS 
 
SENSITIVE 
 
STATE FOR EUR/NCE/MSESSUMS 
STATE PASS USTR FOR DONNELLY/ERRION/WEISEL 
COMMERCE FOR 4232/ITA/MAC/EUR/OECA/MROGERS 
 
REF: (A) Warsaw 0068 (B) Warsaw 0280 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR PL
SUBJECT: POLAND: Comment on Pharma's Special 301 Input 
 
 
------- 
Summary 
------- 
 
1. (U) Sensitive but unclassified.  Not for distribution 
outside USG. 
 
2. (SBU) Pharma's call for Priority Foreign Country (PFC) 
status for Poland is understandable.  The industry has 
indeed faced many challenges in dealing with the Polish 
government prior to accession, and some of these issues have 
exacerbated dealing with the Ministry of Health in the post- 
accession environment as well.  However, the industry's main 
problem, which has consistently been at the foundation of 
most, if not all, its complaints, has been access to the 
reimbursement list.  And while issues relating to inadequate 
IPR protection played a role in hindering the 
competitiveness of the industry in the late 1990s, data 
exclusivity problems do not appear, given the evidence 
submitted, to be the main culprit in limiting industry's 
effectiveness.  Indeed, we have proposed a strategy (reftel 
A) for dealing with the new government that is already 
bearing fruit, thanks in great measure to the visit Commerce 
Secretary Gutierrez.  In sum, we believe that cooperative 
 
SIPDIS 
engagement is the best way to address industry's main 
complaint: access for innovative drugs to the reimbursement 
list.  End Summary. 
 
----------------------------------- 
Industry's Points: Data Exclusivity 
----------------------------------- 
 
3. (SBU) As we review industry's submission, we find a 
number of complaints, some with more substantive merit than 
others.  But most of the complaints are the same that we 
have read in previous years' submissions.  This does not 
mean the problems should be discounted.  However, it does 
beg the question for this year's review as to what specific 
301-related issues the industry has.  We have discussed this 
very issue with the primary AmCham pharmaceutical group 
(LAWG) as well as with specific companies.  We emphasized 
the need for current actionable examples regarding 
violations of data exclusivity. 
 
4. (SBU) We did get a number of complaints regarding "ghost 
list" drugs and the increasing number of molecules found on 
that list (reftel B), but by industry's admission, some of 
these drugs do not even exist as a marketable product.  Even 
the example of Fozomax, which industry uses in its 
submission as evidence of the data exclusivity problem, is 
not actionable on that basis.  We asked Merck (protect) 
directly if the company could claim the generics competing 
with Fozomax violated its patent (as reported in reftel A). 
The answer was no.  As to Lilly's Zyprexa, we understand 
this drug was subject to IP-related judicial proceedings in 
the United States as well.  Again, this does not diminish 
the threat to industry that Poland's lack of commitment to 
cooperation with the innovative drug industry demonstrates. 
But it does underscore why it is difficult for the Embassy 
to raise data exclusivity violations as a cudgel to gain 
access to the reimbursement list for innovative drugs, and 
why enhancing cooperation and dialogue is far more likely 
than threatening sanctions to get industry what it wants. 
 
5. (SBU) It is true that Poland has not implemented fully 
all data exclusivity directives (65/65 is still pending 
implementation).  But Poland has filed for an exception to 
implementation for full term data exclusivity in accordance 
with EU rules.  From our perspective, it is difficult to 
view this request as substantive IPR violation. 
 
-------------------------------------- 
Industry's Points: Customs and Margins 
-------------------------------------- 
 
6. (SBU) Industry has been rightly concerned about this 
issue, as the potential damage could be catastrophic, with 
literally hundreds of millions of dollars in financial 
penalties at stake.  However, the issue has been winding its 
way through the Polish courts, which have been consistently 
rendering decisions in industry's favour.  And while the 
case is still in court, the Minister of Health himself is 
pressing U.S. officials and industry to look for a 
settlement "out of court."  Previously, industry had been 
eager to pursue this approach as well.  Now, it smells 
blood, and an out of court settlement appears unlikely.  We 
support industry's position on the substance of the issue. 
As to the tactics related to resolving it, we of course 
defer to the LAWG.  However, given that the case is being 
handled without any undue political interference, we believe 
the issue does not rise to the level that would warrant an 
elevation of Poland's watch list status. 
 
---------------------- 
Give Dialogue a Chance 
---------------------- 
 
7. (SBU) Perhaps the most compelling reason to avert raising 
Poland's status is the fact that we now are dealing with a 
new government, which in meetings with Embassy officials and 
Washington visitors has impressed us with its desire to 
engage with us and industry to resolve problems on the IPR 
front.  In discussions with Secretary Gutierrez, Minister 
Religa gave reassuring answers to the Secretary's points 
about innovative drug access to the reimbursement list 
(again this is *the* major issue for industry).  Religa, a 
medical doctor and not a PiS party member, appeared genuine 
when he expressed both his desire to add innovative drugs to 
the reimbursement list and difficulties in dealing with the 
Finance Ministry to obtain the necessary budget to do it. 
While words and deeds, of course, need to be brought into 
synch, we nonetheless believe it is important to give 
substantive engagement a chance.  As reported, we are 
currently working to establish a regular dialogue between 
industry and the Health Ministry that we hope will resolve 
the thorniest outstanding issues.  It would send the wrong 
message to this Polish government if we were to use the 
stick as our opening gambit.